Furthermore, a combination of the STING and the TLR agonist induced a downregulation of alpha smooth muscle actin (αSMA) and vimentin (VIM) which are important markers for CAFs, suggesting that the combination strategy has the potential to suppress tumor‐promoting effects of CAFs in a mouse model of colon cancer.[83] Of note, the underlying mechanisms for this effect will require further investigation. The gene discussed is VIM; the disease is neoplasm.